Akebia Ther Total Liabilities
Akebia Ther total liabilities. Based on the latest financial reports, Akebia Ther (AKBA) has total liabilities worth $343.95 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AKBA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Akebia Ther (2012–2025)
Total liabilities of Akebia Ther from 2012 to 2025. This chart illustrates how Akebia Ther's total liabilities have evolved over time, based on quarterly financial data.
Akebia Ther Competitors by Total Liabilities
The table below lists competitors of Akebia Ther ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hitit Bilgisayar Hizmetleri AS
IS:HTTBT
|
Turkey | TL655.34 Million |
|
Kona I Co.Ltd
KQ:052400
|
Korea | ₩307.29 Billion |
|
Uxin Ltd
NASDAQ:UXIN
|
USA | $2.12 Billion |
|
ZKH Group Limited
NYSE:ZKH
|
USA | $3.36 Billion |
|
United Bankers Oyj
HE:UNITED
|
Finland | €38.51 Million |
|
Nanhua Instruments Co Ltd
SHE:300417
|
China | CN¥89.85 Million |
|
AgriFORCE Growing Systems Ltd
NASDAQ:AGRI
|
USA | $4.36 Million |
|
Lyko Group A
ST:LYKO-A
|
Sweden | Skr2.07 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Akebia Ther's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Akebia Ther.
Liquidity & Leverage Metrics
Akebia Ther Total Liabilities Ratios Explained
Akebia Ther total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akebia Ther's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akebia Ther (2012–2025)
The table below shows the annual total liabilities of Akebia Ther from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $343.95 Million | +27.46% |
| 2024-12-31 | $269.86 Million | -0.89% |
| 2023-12-31 | $272.29 Million | -22.39% |
| 2022-12-31 | $350.82 Million | -22.95% |
| 2021-12-31 | $455.34 Million | +14.83% |
| 2020-12-31 | $396.52 Million | +5.33% |
| 2019-12-31 | $376.44 Million | +4.39% |
| 2018-12-31 | $360.61 Million | +47.24% |
| 2017-12-31 | $244.92 Million | +5.52% |
| 2016-12-31 | $232.10 Million | +1843.53% |
| 2015-12-31 | $11.94 Million | +72.65% |
| 2014-12-31 | $6.92 Million | +76.91% |
| 2013-12-31 | $3.91 Million | -20.59% |
| 2012-12-31 | $4.92 Million | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more